CURRICULUM VITAE

Stanley Lipkowitz, M.D., Ph.D.

Senior Investigator, LCMB, CCR, NCI

[Address]{.underline}: Laboratory of Cellular and Molecular Biology

Center for Cancer Reseach, NCI

Blg 37, Room 2066

37 Convent Drive MSC 4255

Bethesda, MD 20892-4255

Phone: (301) 402-4276

FAX: (301) 496-8479

email: lipkowis@mail.nih.gov

[Citizenship]{.underline}: United States

[Education]{.underline}:

1977 A.B. (Biology), School of Arts and Sciences, Cornell University,
Ithaca, NY

> 1983 Ph.D. (Biochemistry), Cornell University Graduate School of
> Medical Sciences, New York, NY

1984 M.D., Cornell University Medical College, New York, NY

[Clinical Training]{.underline}:

1984-1987 Intern and Resident in Internal Medicine, The New York
Hospital, New York, NY

1986-1987 Assistant Chief Resident (Medicine), Memorial-Sloan Kettering
Cancer Center, New York, NY

1987-1990 Fellow in Medical Oncology, National Cancer Institute,
Bethesda, MD,

[Chronology of Employment]{.underline}:

1988-1997 Clinical Associate (Medical Oncology), National Cancer
Institute,Bethesda, MD

1988-1990 Adjunct Instructor of Medicine, Uniformed Services University
of the Health Sciences, Bethesda, MD

1990-1993 Adjunct Assistant Professor of Medicine, Uniformed Services
University of the Health Sciences, Bethesda, MD

1993-2006 Adjunct Associate Professor of Medicine, Uniformed Services
University of the Health Sciences, Bethesda, MD

1997-present Adjunct Faculty, Molecular and Cell Biology Graduate
Program, Uniformed Services University of the Health Sciences, Bethesda,
MD

2006-present Adjunct Professor of Medicine, Uniformed Services
University of the Health Sciences, Bethesda, MD

1997-2003 Investigator, Genetics Branch, Center for Cancer Research,
National Cancer Institute, Bethesda, MD

2003-2006 Investigator, Laboratory of Cellular and Molecular Biology,
Center for Cancer Research, National Cancer Institute, Bethesda, MD

2006-Present Senior Investigator, Laboratory of Cellular and Molecular
Biology, Center for Cancer Research, National Cancer Institute,
Bethesda, MD

[Uniformed Service]{.underline}:

1991-1998 Public Heath Service

[Medical Licensure and Board Certification]{.underline}:

1985 Diplomat, National Board of Medical Examiners

1987 Diplomat, American Board of Internal Medicine

1989 Diplomat, Medical Oncology Subspecialty Board

1985-present New York Medical License (inactive)

1987-present Maryland Medical License

[Scientific Societies]{.underline}:

American Association for the Advancement of Science

American Association for Cancer Research

American Society of Clinical Oncology

New York Academy of Sciences

[Editorial Boards]{.underline}:

Associate Editor, Clinical Cancer Research (2002-Present)

Guest Editor, Breast Diseases (2002)

Editorial Board Member, Breast Diseases (2004-Present)

[Honors and Other Special Scientific Recognition]{.underline}:

New York State Regents Scholarship, 1973

National Merit Letter of Commendation, 1973

Phi Beta Kappa, 1977

A.B. Cum Laude in Biology with Distinction in All Subjects, 1977

Insurance Fund Medical Scientist Scholarship, 1978-1984

Alpha Omega Alpha Honor Medical Society, 1986

Technology Transfer Award from NCI, 1994

PHS Unit Commendation, 1995

PHS Bicentennial Unit Commendation, 1997

NCI Directors Innovation Award for Identification of Molecular Targets
in ER-, PR- Her2/Neu- Breast Cancer, 2006

[Meeting Chairs, Boards, and Committees]{.underline}:

Extramural:

Co-Chair, Receptor Tyrosine Kinases in Cancer Minisyposium at AACR
Annual Meeting, April 19, 2005

AACR Program Committee for 2005 Annual Meeting, Cell Growth Signaling
Pathways

ASCO Education Committee (Track Leader for Tumor Biology) 2006-Present

ASCO Scientific Program Committee (Tumor Biology) 2006-Present

Triggering Apoptosis National Advisory Board, Genentech, 2006-Present

[Meeting Chairs and Committees (con't)]{.underline}:

Intramural:

Chair, Tyrosine Kinase Inhibitors in the Treatment of Cancer at
Molecular Targets Faculty Meeting, Bethesda, MD. October 22, 2001.

Chair, Genetic Predisposition to Breast Cancer at Breast Cancer Faculty
Round Table Discussion. Bethesda, MD. March 24, 2003

Chair, Signal Transduction and Gene Expression, CCR Fellows and Young
Investigators Retreat, March 1, 2005

Chair, Biomarkers for Early Detection, Combined Faculty Retreat, July
21, 2005

Panel Member, Round Table Discussion on Interaction of the Faculty with
the rest of the CCR. NCI Chemistry and Structural Biology Faculty,
Gaithersburg, MD. January 28, 2002

CoDirector, Graduate Partnership Program with George Washington
University (2006-Present)

Member, Clinical Tenure Review Panel (2007- present)

Steering Committee, Breast Cancer Faculty, NCI

Steering Committee, Molecular Targets Drug Discovery Program, NCI

Member, Molecular Targets Faculty, NCI

Member, Cellular, Molecular and Developmental Biology Faculty, NCI

[Clinical Activities]{.underline}:

Attending, Oncology Inpatient Service, Clinic, and Consult Service
(1990-Present)

Attending, Breast Care Center (2000-Present)

Clinical Trials:

Biomarker assays in nipple aspirate fluid (Associate Investigator)

A Pilot Study to Evaluate Epidermal Growth Factor Receptor Signaling
after Treatment with Oral OSI-774 in Patients with Locally Advanced or
Metastatic Breast Cancer (Associate Investigator)

A Randomized Comparison of Group versus Individual Genetic Education and
Counseling for Individuals with Risk of Familial Breast and/or Ovarian
Cancer (Associate Investigator)

Acquisition of Blood, Bone Marrow, Tumor or Tissue Samples
(Co-investigator).

A phase II Study to evaluate the efficacy and safety using combined
monoclonal antibodies, trastuzumab and pertuzumab, in subjects with
Her-2 overexpressed locally advanced and metastatic breast cancer
(Associate Investigator)

[Teaching Activities]{.underline}:

NNMC Breast Cancer Lectures for Medical Oncology Fellows (2005-present)

Cell Biology Course for USUHS Molecular and Cell Biology Program (1999
--Present)

USUHS Graduate Course on Mechanisms of Growth Control in Neoplasia
(2001)

[Postdoctoral Fellows and Students]{.underline}:

Maccon Keane Postdoctoral Fellow (1994-1999)

ASCO Young Investigator Award Recipient (1997)

Currently: Director, Galway Cancer Center, Galway, Ireland

Yaffa Rubinstein Postdoctoral Fellow (1998-2000)

Currently: Program Director for the Cooperative Human Tissue Network

Cancer Diagnosis Program, DCTD, NCI

Seth Ettenberg Ph.D. student USUHS Molecular and Cell Biology Program
(1997-2001)

Postdoctoral Fellow (2001)

Currently: Lab Head, Oncology Antibodies

Novartis Institutes for Biomedical Research, Cambridge, MA

Mauricio Cuello Postdoctoral Fellow (1999-2001)

Currently: Auxillary Professor of Gynecological Oncology

Pontificia Universidad Católica de Chile

Isaac Darko UGSP Scholar (2001-2002)

Currently: M.D. student

Mount Sinai Medical School

Ashely Coats Post-baccalaureate Fellow (2001-2003)

Currently: M.D.-Ph.D. student

University of Pennsylvania

Jing Bao Postdoctoral Fellow (2002- 2004)

Currently: Technology Transfer Specialist, NIMH, NIH

Nina Sivadasan Post-baccalaureate Fellow (2003- 2004)

Currently: M.D. Student

Robert Wood Johnson Medical School

Joseph Kovacs Howard Hughes Medical Institute Student Fellowship
(2004-2005)

Currently: Undergraduate

Cornell University College of Arts and Sciences

Gareth Davies Postdoctoral Fellow (2002- 2006)

FARE Award Recipient (2005)

Currently: Post Doctoral Fellow

The Institute for Cancer Research, London, UK

Jeremy Karlin Post-baccalaureate Fellow (2004-2006)

Currently: M.D. Student

Virginia Commonwealth University School of Medicine

Monzur Rahman Postdoctoral Fellow (2002- Present)

Philip Ryan Ph.D. student, NIH Graduate Partnership Program
(2004-Present)

Lyndsay Murrow Post-baccalaureate Fellow (2006-Present)

Stephen Kales Postdoctoral Fellow (2006-Present)

[Ph.D. Qualification and Thesis Committees]{.underline}:

Constance Cultraro Thesis Committee, Genetics Program, George Washington
University (1998)

Amy Coxon Thesis Committee, Genetics Program, George Washington
University (1999)

Seth Ettenberg Thesis Committee (Major Sponsor), Molecular and Cell
Biology Program, Uniformed Services University of the Health Sciences
(2001)

John Karaian Ph.D. Qualifying Committee, Molecular and Cell Biology
Program, Uniformed Services University of the Health Sciences (2004)

Gene Garcia Ph.D. Graduate Board Oral Examination Committee, Johns
Hopkins University (2005)

Ph.D. Thesis Interim Review Committee, Johns Hopkins University (2006)

Philip Ryan Ph.D. Qualifying Committee (Major Sponsor), NIH Graduate
Parnership Program with George Washington University (2006)

[Peer Review]{.underline}:

Grant Review:

Canadian Breast Cancer Research Initiative (1999-2000)

The Dutch Cancer Society (ad hoc reviewer: 2000)

Italian Association For Cancer Research (ad hoc reviewer:2004, 2005)

High Q Foundation/MRSSI, Inc (ad hoc reviewer: 2005)

MRC Senior Non Clinical Fellowship (ad hoc reviewer: 2005)

Ohio Cancer Research Associates (ad hoc reviewer: 2006)

Manuscript Review:

American Journal of Pathology

Biochimica et Biophysica Acta

Blood

BMC Cancer

Breast Cancer Research

Cancer

Cancer Detection and Prevention

Cancer Letters

Cancer Research

Cell

Cell Death and Differentiation

Cell Biology International

Clinical Cancer Research

Current Biology

Current Immunology Reviews

EMBO

European Journal of Cancer

Experimental Cell Research

Genes & Development

Immunity

Immunology and Cell Biology

Journal of Biological Chemistry

Journal of Leukocyte Biology

Journal of the National Cancer Institute

Molecular and Cellular Biology

Molecular Cancer Research

Nature Medicine

Nature Reviews Molecular Cell Biology

Oncogene

PNAS

**PUBLICATIONS**

**Articles:**

1\. Hess GP, **Lipkowitz S**, Struve GE. Acetylcholine-receptor‑mediated
ion flux in electroplax membrane microsacs (vesicles): Change in
mechanism produced by asymmetrical distribution of sodium and potassium
ions. Proc Natl Acad Sci (USA) **75**: 1703‑1707, 1978.

2\. **Lipkowitz S**, Rubin AL, Stenzel KH, Novogrodsky A. Cellular and
growth factor requirements for activation of human T lymphocytes by
neuraminidase and galactose oxidase-treated cells. J Immunol **130**:
2702-2707, 1983.

3\. **Lipkowitz S**, Greene WC, Rubin AL, Novogrodsky A, Stenzel KH.
Expression of receptors for interleukin-2: Role in the commitment of T
lymphocytes to proliferate. J Immunol **132**: 31‑37, 1984.

4\. Arnold A, **Lipkowitz S**, Suthanthiran M, Novogrodsky A, Stenzel
KH. Human B lymphoblastoid cell lines produce an interleukin-1 like
signal for mitogen-treated T-lymphocytes via direct cell contact. J
Immunol **134**: 3876-3881, 1985.

5\. Stern MH, **Lipkowitz S**, Aurias A, Griscelli C, Thomas G, Kirsch
IR. Inversion of chromosome 7 in ataxia telangiectasia is generated by a
rearrangement between T-cell receptor beta and T‑cell receptor gamma
genes. Blood **74**: 2076-2080, 1989.

6\. **Lipkowitz S**, Stern MH, Kirsch IR. Hybrid T-cell receptor genes
formed by interlocus recombination in normal and ataxia-telangiectasia
lymphocytes. J Exp Med **172**: 409-418, 1990.

7\. Begley CG, **Lipkowitz S**, Göbel V, Mahon KA, Bertness V, Green AR,
Visvader J, Gough NM, Kirsch IR. Molecular characterization of NSCL, a
gene encoding a helix-loop-helix protein expressed in the developing
nervous system. Proc Natl Acad Sci (USA) **89**: 38-42, 1992.

8\. Göbel V, **Lipkowitz S**, Kozak CA, Kirsch IR: NSCL-2: A
basic-helix-loop-helix gene expressed in early neurogenesis. Cell Growth
and Differentiation **3**: 143-148, 1992.

9\. **Lipkowitz S**, Garry VF, Kirsch IR. Interlocus V(D)J recombination
as a measure of genomic instability in agriculture workers at risk of
developing lymphoid malignancies. Proc Natl Acad Sci (USA) **89**:
5301-5305, 1992.

10\. Gough NM, **Lipkowitz S**, Kirsch IR, Begley CG. Localization of
murine HLH gene NSCL to chromosome 1 using recombinant inbred strains.
Mammalian Genome **3**: 182-183, 1992.

11\. **Lipkowitz S**, Göbel V, Varterasian M, Nakahara K, Tchorz K,
Kirsch IR. A comparative structural characterization of the human NSCL-1
and NSCl-2 genes: Two basic-helix-loop-helix genes expressed in the
developing nervous system. J Biol Chem **267**: 21065-21071, 1992.

12\. Varterasian M, **Lipkowitz S**, Karsch-Mizrachi I, Paterson B,
Kirsch IR. Two new *Drosophila* genes related to human hematopoietic and
neurogenic transcription factors. Cell Growth and Differentiation **4**:
885-889, 1993.

13\. Keane MM, Rivero-Lezcano OM, Mitchell JA, Robbins KC, **Lipkowitz
S**. Cloning and characterization of cbl-b: A SH3 binding protein with
homology to the c-cbl proto-oncogene. Oncogene **10**: 2367-2377, 1995.

14\. Keane MM, Lowrey GA, Ettenberg SA, Dayton MA, **Lipkowitz S**. The
protein tyrosine phosphatase DEP-1 is induced during differentiation and
inhibits growth of breast cancer cells. Cancer Research **56**:
4236-4243, 1996.

15\. Keane MM, Ettenberg SA, Lowrey GA, Russell EK, **Lipkowitz S**. Fas
expression and function in normal and malignant breast cell lines.
Cancer Research **56**, 4791-4798, 1996.

16\. Chen W, Otterson GA, **Lipkowitz S**, Khleif SN, Coxon AB, Kaye FJ.
Apoptosis is associated with cleavage of a 5 kDa fragment from RB which
mimics dephosphorylation and modulates E2F binding. Oncogene **14**:
1243-1248, 1997.

17\. Liu Y-C, Liu Y, Elly C, Yoshida H, **Lipkowitz S**, Altman A.
Serine Phosphorylation of Cbl induced by phorbol ester enhances its
association with 14-3-3 proteins in T cells via a novel serine-rich
14-3-3 binding motif. J Biol Chem **272**, 9979-9986, 1997.

18\. Keane MM, Ettenberg SA, Nau MM, Russell EK, **Lipkowitz S**.
Chemotherapy augments TRAIL induced apoptosis in breast cell lines.
Cancer Research **59**, 734-741, 1999.

19\. Elly C, Witte S, Zhang ZH, Rosnet O, **Lipkowitz S**, Altman A, Liu
Y-C. Tyrosine phophorylation and complex formation of cbl-b upon T cell
receptor stimulation. Oncogene **18**, 1147-1156, 1999.

20\. Ettenberg SA, Keane MM, Nau MM, Frankel M, Wang LM, Pierce JH,
**Lipkowitz S**. cbl-b inhibits epidermal growth factor receptor
signaling. Oncogene **18**, 1855-1866, 1999.

21\. Keane MM, Ettenberg SA, Nau MM, Banerjee P, Cuello M, Penninger JM,
**Lipkowitz S**. cbl-3: a new mammalian cbl family protein. Oncogene
**18**, 3365-3375, 1999.

22\. Chen W, Geradts J, M. Keane MM, **Lipkowitz S**, Zajac-Kaye M, and
Frederic J. Kaye FJ. The 100-kDa proteolytic fragment of RB is retained
predominantly within the nuclear compartment of apoptotic cells.
Molecular Cell Biology Research Communications **1**, 216-220, 1999.

23\. Ettenberg SA, Rubinstein, YR, Banerjee P, Nau MM, Keane MM,
**Lipkowitz S**. cbl-b inhibits EGF-receptor induced apoptosis by
enhancing ubiquitination and degradation of activated receptors.
Molecular Cell Biology Research Communications **2**, 111-118, 1999.

24\. Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy
I, Lavi S, Iwai K, Reiss Y, Ciechanover A, **Lipkowitz S**, Yarden Y.
Ubiquitin ligase activity and tyrosine phosphorylation underlie
suppression of growth factor signaling by c-cbl/sli-1. Molecular Cell
**4**, 1029-1040, 1999.

25\. Buchmaier K, Krawczyk C, Kozieradzki I, Kong YY, Sasaki T,
Oliveira-dos-Santos A, Mariathasan S, Bouchard D, Wakeman A, Itie A, Le
J, Ohashi PS, Sarosi I, Nishina H, **Lipkowitz S**, Penninger JM.
Negative regulation of lymphocyte activation and autoimmunity by the
molecular adaptor cbl-b. Nature **403**, 216, 2000.

26\. Lin Y, Devin A, Cook A, Keane MM, Kelliher M, Lipkowitz S, Liu ZG.
The death domain kinase RIP is essential for TRAIL (Apo2L)-induced
activation of IkappaB kinase and C-Jun N-terminal kinase. Mol Cell Biol
20, 6638-6645, 2000.

27\. Keane MM, Rubinstein YR, Cuello M, Ettenberg SA, Banerjee P, Nau
MM, **Lipkowitz S**. Inhibition of NF-B enhances TRAIL mediated
apoptosis in breast cancer cell lines. Breast Cancer Research and
Treatment **64**: 211-219, 2000.

28\. Borinstein SC, Fox MA, Hyatt MA, Sykes VW, Straub RE, **Lipkowitz
S**, Boulter J, Bogler O. SETA is a multifunctional adapter protein with
3 SH3 domains that binds the novel protein SB1, as well as Grb2 and cbl
proteins. Cellular Signalling **12**: 769-779, 2000.

29\. Cuello M, Ettenberg SA, Nau MM, **Lipkowitz S**. Synergistic
induction of apoptosis by the combination of TRAIL and chemotherapy in
chemoresistant ovarian cancer cells. Gynecol Oncol **81**: 380-90, 2001.

30\. Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM,
Dennis PA, **Lipkowitz S**. Downregulation of the erbB-2 receptor by
trastuzumab (Herceptin) enhances TRAIL-mediated apoptosis in breast and
ovarian cancer cell lines which overexpress erbB-2. Cancer Research
**61**: 4892-4900, 2001.

31\. Ettenberg SA, Magnifico A, Cuello M, Nau MM, Rubinstein YR, Yarden
Y, Weissman AM, **Lipkowitz S**. Cbl-b-dependent coordinated degradation
of the epidermal growth factor receptor signaling complex.. J Biol Chem
**276**: 27677-27684, 2001.

32\. Klein P, Glaser E, Grogan L, Keane M, **Lipkowitz S**, DeMarini D,
Soballe P, Brooks L, Jenkins J, Steinberg S, Kirsch I. Biomarker assays
in nipple aspirate fluid. The Breast Journal **7**; 378-387, 2001.

33\. Sattler M, Pride YB, Quinnan LR, Verma S, Malouf NA, Husson H,
Salgia R, **Lipkowitz S**, Griffin JD. Differential expression and
signaling of CBL andCBL-B in BCR/ABL transformed cells. Oncogene **21**:
1423-1433, 2002

34\. Zhang J, Bárdos T, Li D, Gál I, Vermes C, Xu J, Mikecz K, Finnegan
A, **Lipkowitz S**, Glant TT. Cutting Edge: Regulation of T Cell
activation threshold by CD28 costimulation through targeting Cbl-b for
ubiquitination. J Immunol **169**: 2236-2240, 2002.

35\. Szymkiewicz I, Kowanetz K, Soubeyran P, Dinarina A, **Lipkowitz
S**, Dikic I. CIN85 participates in Cbl-b-mediated downregulation of
receptor tyrosine kinases. J Biol Chem **277**: 39666-39672, 2002.

36\. Nau MM, **Lipkowitz S**. Comparative Genomic Organization of the
Human *cbl* Genes. Gene **308**: 103-113, 2003.

37\. Griffiths GK, Sanchez O, Mill P, Krawczyk C, Hojilla CV, Rubin E,
Nau MM, Khokha R, **Lipkowitz S**, Hui CC, Penninger JM. Cbl-3-deficient
mice exhibit normal epithelial development. Mol Cell Biol **23**:
7708-7718, 2003.

38\. Magnifico A, Ettenberg S, Tiwari S, Yang C, Lipkowitz S, Weissman
AM. WW domain HECT E3s target Cbl RING finger E3s for proteasomal
degradation.: J Biol Chem 278: 43169-43177, 2003.

39\. Cuello M, Coats A, Ettenberg SA, Gardner GJ, Nau MM, Liu JR, Birrer
MJ, **Lipkowitz S**. N-(4-hydroxyphenyl) retinamide (4HPR) enhances
TRAIL-mediated apoptosis through enhancement of a
mitochondrial-dependent amplification loop in ovarian cancer cell lines.
Cell Death and Differentiation **11**: 527-541, 2004.

40\. Rahman L,Voeller D, Rahman M, **Lipkowitz S**, Allegra C, Kaye FJ,
Maria Zajac-Kaye. Thymidylate Synthase as an oncogene: a novel role for
an essential DNA synthesis enzyme. Cancer Cell **5**: 341-351, 2004.

41\. Peschard P, Ishiyama N, Lin T, **Lipkowitz S**, Park M. A Conserved
DYR Motif in the Met Receptor Family Forms an Atypical c-Cbl TKB Domain
Binding Site Required for Suppression of Oncogenic Activation. J Biol
Chem **279**: 29565-29571, 2004.

42\. Tan AR, Yang X, Hewitt SM, Berman A, Lepper ER, Sparreboom A, Parr
AL, Figg WD, Chow C, Steinberg SM, Bacharach SL, Whatley M, Carrasquillo
JA, Brahim JS, Ettenberg SA, **Lipkowitz S**, Swain SM. Evaluation of
biologic end points and pharmacokinetics in patients with metastatic
breast cancer after treatment with erlotinib, an epidermal growth factor
receptor tyrosine kinase inhibitor. J Clin Oncol **22**: 3080-90, 2004.

43\. Davies GC, Ettenberg SA, Coats AO, Mussante M, Ravichandran S,
Collins JR, Nau MM, **Lipkowitz S**. Cbl-b interacts with ubiquitinated
proteins; differential functions of the UBA domains of c-Cbl and Cbl-b.
Oncogene **23**: 7104-15, 2004.

44\. Zeng S, Xu Z, **Lipkowitz S**, Longley JB. Regulation of stem cell
factor receptor signaling by Cbl family proteins (CBL-B/c-CBL). Blood
**105**: 226-232, 2005.

45\. Calzone KA, Prindiville S, Jourkiv O, Jenkins J, DeCarvalho M,
Wallerstedt D, Liewehr DJ, Steinberg S, Soballe S, **Lipkowitz S**,
Klein P, Kirsch IR. A Randomized Comparison of Group versus Individual
Genetic Education and Counseling for Individuals with Risk of Familial
Breast and/or Ovarian Cancer. J Clin Oncol **23**: 3455-3464, 2005.

46\. Choong NW, Dietrich S, Seiwert T, Tretiakova M, Davies GS,
**Lipkowitz S**, Husain A, Salgia R, Ma PC. EGFR Mutation and
Differential Response to Erlotinib and Gefitinib in Lung Cancer. Nature
Clinical Practice Oncology **3**: 50-57, 2006.

47\. Davies GC, Ryan PE, Rahman L, Zajac-Kaye M**, Lipkowitz S**.
EGFRvIII undergoes activation induced down-regulation mediated by the
Cbl proteins. Oncogene **25**: 6497-6509, 2006.

48\. Sadarangani A, Kato S, Espinoza N, Lange S, Llados C, Espinosa M,
Villalón M, **Lipkowitz S**, Cuello M, Owen GI. TRAIL mediates apoptosis
in cancerous but not normal primary cultured cells of the human
reproductive tract. Apoptosis **12**: 73-85, 2007.

**Letters and Commentaries:**

1\. Karlin JD, Nguyen D, Yang SX, **Lipkowitz S**. Epidermal Growth
Factor Receptor Expression in Breast Cancer. J Clin Oncol **23**:
8119-8120, 2005.

**2. Lipkowitz S,** Dennis PA**.** PPAR agonists follow an unknown
TRAIL in lung cancer. Cancer Biol Ther **6**: 2007 \[Epub ahead of
print\].

**Reviews:**

1\. Kirsch IR, **Lipkowitz S**. A Measure of genomic instability and its
relevance to lymphomagenesis. Cancer Research (Suppl.) **52**:
5545s-5546s, 1992.

2\. **Lipkowitz S**. Invited comments on "The use of the polymerase
chain reaction in clinical oncology". Oncology **6**: 39-40, 1993.

3 Kirsch IR, Abdallah JM, Bertness VL, Hale M, **Lipkowitz S**, Lista F,
Lombardi DP. Lymphocyte-specific genetic instability and cancer. Cold
Spring Harbor Symposia on Quantitative Biology, 59: 287-295, 1994.

4\. **Lipkowitz S.** Introduction: Novel targets in breast cancer.
Breast Disease 15: 1-2, 2002.

5\. Cuello MA, Marion Nau MM, **Lipkowitz S**. Apoptosis and the
treatment of breast cancer. Breast Disease **15**: 71-82, 2002.

6\. **Lipkowitz S.** Ubiquitin mediated degradation of growth factor
receptors in the pathogenesis and treatment of cancer. Breast Cancer
Research **5**: 8-15, 2003.

7\. Ryan PE, Davies GC, Nau MN, **Lipkowitz S**. Regulating the
regulator: Negative regulation of Cbl ubiquitin ligases. TIBS **31**:
79-88, 2006. ***Article featured on cover.***

8\. Davies GC, **Lipkowitz S**. Differential Functions of the
ubiquitin-associated domains of Cbl and Cbl-b proteins: "Cblings" but
not twins. CCR Frontiers in Science **5**: 6-8, 2006**.**

9\. Cuello MF, Kato SC, Sadarangani AK, Saez CS, Gejman RE, Owen G,
**Lipkowitz S**. Receptor mediated cell death: role of ovarian steroid
hormones in TRAIL induced apoptosis in gynecologic cancers. Bulletin of
the School of Medicine of Chile. **31**: 5-16, 2006.

**Book Chapters:**

1\. **Lipkowitz S**. Activation of human T lymphocytes by aldehyde
bearing cells. Thesis, Cornell University Graduate School of Medical
Sciences, New York, NY 1983.

2\. Kirsch IR, Aplan PD, Begley CG, Bertness V, **Lipkowitz S**,
Nakahara K, Nussmeier M, Felix CA, Reynolds L, Seible NL, Stern MH,
Tchorz K: Abnormal antigen receptor formation in normal,
ataxia-telangiectasia, and malignant lymphocytes. In: Advances in gene
technology: The molecular biology of immune diseases and the immune
response. Streilein JW, Ahmad F, Bialy H, Black S, Blomberg B, Chin YH,
Lopez D, Malek T, Podack ER, Rabin MB, Stein-Streilein J, Van Bunt J,
Whelan WJ. eds. **10**: 22-34, 1990.

3\. **Lipkowitz S**, Kirsch IR. Hybrid antigen receptor genes: A model
of translocation in lymphoid cells and a marker for the risk of
developing a lymphoid malignancy. In: The causes and consequences of
chromosomal aberrations. IR Kirsch ed. CRC Press, Boca Raton, Fla.,
1993.

4\. Khong HT, **Lipkowitz S**. Carcinoma of Unknown Primary. In:
Bethesda Handbook of Clinical Oncology. J Abraham and CJ Allegra eds.
Lippincott, Williams, & Wilkins. Baltimore, MD. 2001.

5\. Davies GC, **Lipkowitz S**. Ubiquitin mediated down-regulation of
receptor tyrosine kinases and cancer. Proceedings of the American
Association of Cancer Research Educational Book. 157-161, 2006.

**INVITED PRESENTATIONS**

1\. Research Seminar. Laboratory of Environmental Medicine and
Pathology, University of Minnesota, Minneapolis, MN. October 1, 1991.

2\. Research Seminar. Hematology Section, Department of Medicine, Boston
University, Boston, MA. December 18, 1991.

3\. Research Seminar. Picower Institute for Medical Research,
Mannhasset, NY. January 17, 1992.

4\. Research Seminar. Fox Chase Cancer Center, Philidelphia, PA.
February 12, 1992.

5\. Research Seminar. Massachesetts General Cancer Center, Boston, MA.
February 20, 1992.

6\. Research Seminar. Lombardi Cancer Center, Georgetown University,
Washington, D.C. February 24, 1992.

7\. Research Seminar. Simmons Cancer Center, University of Texas
Southwestern, Dallas, TX. March 25, 1992.

8\. Research Seminar. University of Michigan Cancer Center, Ann Arbor,
MI. November 12, 1992.

9\. Research Seminar. The Sidney Kimmel Comprehensive Cancer Center,
Johns Hopkins University, Baltimore, MD. April 22, 1993.

10\. Research Seminar. Gene Therapy Meeting sponsored by the Leukemia
Society of America, Dublin, Ireland. September 18-21, 1994.

11\. Research Seminar. Karmanos Cancer Institute, Wayne State
Univeristy, Detroit, MI. October 15,1996.

12\. Research Seminar. NIH Apoptosis Interest Group Seminar, Bethesda,
MD. April 5, 1997.

13\. Research Seminar. Molecular and Cell Biology Department, Uniformed
Services University of the Health Sciences, Bethesda MD. October 7,
1998.

14\. Research Seminar. Cbl Workshop at the 10^th^ International
Conference on Second Messengers and Phosphoproteins. Jerusalem, Israel.
November 11, 1998.

15\. Research Seminar. Department of Biological Regulation, The Weizmann
Institute of Science, Rehovot, Israel. November 15, 1998.

16\. Research Seminar. Laboratory of Molecular Biology, DBS, NCI,
Bethesda, MD. January 5, 2001.

17\. Research Seminar. NIH Apoptosis Interest Group Seminar, Bethesda,
MD. February 5, 2001.

18\. Research Seminar. Mechanisms of Growth Control in Neoplasia Lecture
Series, Uniformed University of the Health Sciences, Bethesda, MD. March
2, 2001.

19\. Research Seminar. NCI Cellular, Molecular, and Developmental
Biology Faculty Meeting, Gaithersburg, MD. April 18, 2002.

20\. Research Seminar. Molecular Targets Drug Development Program, NCI,
Frederick, MD. April 19, 2002.

21\. Research Seminar. Laboratory of Cellular and Molecular Biology,
NCI, Bethesda, MD. September 18, 2002.

22\. Seminar. Avalon Pharmaceuticals,Germantown, MD. January 20, 2003

23\. Research Seminar. NCI Molecular Targets Retreat, Hunt Valley
Maryland. February 7, 2003.

24\. Research Grand Rounds, H. Lee Moffitt Cancer Center, Tampa,
Florida. May 28, 2003.

25\. Research Seminar. Department of Microbiology and Immunology, Temple
University School of Medicine, Philadelphia, PA. June 3, 2003.

26\. Research Seminar. Molecular and Cell Biology Program Seminar,
Uniformed University of the Health Sciences, Bethesda, MD. October 8,
2003.

27\. Visiting Professor and Research Seminar. Ludwig Institute for
Cancer Research, Lausanne, Switzerland. November 7, 2003.

28\. Research Seminar. The Lankenau Institute for Medical Research,
Wynnewood, PA. January 22, 2004

29\. Research Seminar, Department of Biochemistry, National University
of Ireland, Galway, Ireland. April 29, 2004.

30\. Research Seminar, Medical Grand Rounds, Department of Medicine,
National University of Ireland, Galway, Ireland. April 30, 2004.

31\. Research Seminar, Hematology/Oncology Grand Rounds, University of
Chicago, Chicago, Il. November 15, 2004.

32\. Research Seminar, Cancer Biology Seminar Series, Evanston
Northwestern Healthcare Research Instititue, Northwestern University,
Evanston, Il. March 15, 2005.

33\. Research Seminar, Lectures in Life Sciences Seminar Series,
Feinberg School of Medicine, Northwestern University, Chicago, Il. March
16, 2005.

34\. Research Seminar, Molecular Medicine Seminar Series, Cornell
University College of Veterinary Medicine, Ithaca, NY. April 25, 2005.

35\. Research Seminar, Department of Medicine, Division of Hematology
and Oncology, Case Western Reserve University School of Medicine,
Cleveland, OH. June 21, 2005.

36\. Research Seminar, Laboratory of Cell Biology, NHLBI, Bethesda, MD.
September 15, 2005.

37\. Research Seminar, Department of Pharmacology, University of Iowa,
Iowa City, IA. October 11, 2005.

38\. Seminar, AACR Annual Meeting Educational Session,
Ubiquitin-mediated pathways and cancer, Washington, DC. April 1, 2006.

39\. Seminar, Uniformed University of the Health Sciences Research Day
Symposium on Cancer Research. Bethesda, MD. May 18, 2006.

40\. Discussant, Clinical Science Symposium on Triggering Cell Death by
Targeting TRAIL Receptor and Survivin at ASCO Annual Meeting. June 3,
2006

41\. Research seminar, Vermont Cancer Center, Burlington, VT. July 27,
2006.

42\. Seminar, Breast Cancer Course. National Naval Medical Center,
Bethesda, MD. September 21, 2006.

43\. Research Seminar, Apoptosis Thought Leader Summitt, Scottsdale, AZ,
October 7, 2006.

44\. Research Seminar, Division of Monoclonal Antibodies, FDA, Bethesda,
MD, October 30, 2006.

45\. Research Seminar, Avalon Pharmaceuticals,Germantown, MD. January
11, 2007.